Clinical Trials With Pragmatic Elements: A Review of Use Cases and Real-World Data Utilization.

IF 5.5 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Le Su, Lei Chen, Seema Betigeri, Nancy Dreyer, Helga Gardarsdottir, Rachele Hendricks-Sturrup, Mehmet Burcu
{"title":"Clinical Trials With Pragmatic Elements: A Review of Use Cases and Real-World Data Utilization.","authors":"Le Su, Lei Chen, Seema Betigeri, Nancy Dreyer, Helga Gardarsdottir, Rachele Hendricks-Sturrup, Mehmet Burcu","doi":"10.1002/cpt.70033","DOIUrl":null,"url":null,"abstract":"<p><p>Clinical trials with pragmatic elements can capture diverse patient populations, enable efficient follow-up, and reflect routine clinical practices; yet there is limited understanding of their design features, characteristics, and use of real-world data (RWD). Based on a targeted search of PubMed/EMBASE (Jan-2016 to Jul-2024), a review was conducted to characterize clinical trial use cases with pragmatic elements during the design and conduct of trials, as well as clinical trials that utilized RWD for long-term follow-up in the extension phase of the original (\"parent\") trial. A total of 27 use cases were characterized. There were 22 use cases with pragmatic elements, and nearly all employed randomization (n = 21, 95.5%), open-label design (n = 20, 90.9%), with usual/standard of care (n = 13, 59.1%) as comparators. Most generated evidence on both effectiveness and safety (n = 18, 81.8%), primarily in diabetes and cardiovascular disease areas (n = 14, 63.6%). The most common pragmatic elements were broad eligibility criteria, flexible treatment management, minimal or no follow-up, and streamlined endpoint collection. RWD (including electronic health records, claims, registries) was utilized in half of the use cases (n = 4 to enrich trial data with additional information abstracted from RWD; n = 7 to embed trials within routine healthcare databases/systems). In addition, 5 use cases were identified that utilized RWD in the extension phase of the original \"parent\" trials (4 utilizing RWD for long-term follow-up purposes, and one utilizing RWD to construct external controls for clinical trial infrastructure-based extension study). This review underscores the emerging role of pragmatic elements in enhancing trial efficiency, generalizability, and evidence generation on long-term outcomes.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":5.5000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cpt.70033","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Clinical trials with pragmatic elements can capture diverse patient populations, enable efficient follow-up, and reflect routine clinical practices; yet there is limited understanding of their design features, characteristics, and use of real-world data (RWD). Based on a targeted search of PubMed/EMBASE (Jan-2016 to Jul-2024), a review was conducted to characterize clinical trial use cases with pragmatic elements during the design and conduct of trials, as well as clinical trials that utilized RWD for long-term follow-up in the extension phase of the original ("parent") trial. A total of 27 use cases were characterized. There were 22 use cases with pragmatic elements, and nearly all employed randomization (n = 21, 95.5%), open-label design (n = 20, 90.9%), with usual/standard of care (n = 13, 59.1%) as comparators. Most generated evidence on both effectiveness and safety (n = 18, 81.8%), primarily in diabetes and cardiovascular disease areas (n = 14, 63.6%). The most common pragmatic elements were broad eligibility criteria, flexible treatment management, minimal or no follow-up, and streamlined endpoint collection. RWD (including electronic health records, claims, registries) was utilized in half of the use cases (n = 4 to enrich trial data with additional information abstracted from RWD; n = 7 to embed trials within routine healthcare databases/systems). In addition, 5 use cases were identified that utilized RWD in the extension phase of the original "parent" trials (4 utilizing RWD for long-term follow-up purposes, and one utilizing RWD to construct external controls for clinical trial infrastructure-based extension study). This review underscores the emerging role of pragmatic elements in enhancing trial efficiency, generalizability, and evidence generation on long-term outcomes.

具有实用元素的临床试验:用例和真实世界数据利用的回顾。
具有实用因素的临床试验可以捕获不同的患者群体,实现有效的随访,并反映常规临床实践;然而,人们对它们的设计特征、特征和对真实世界数据(RWD)的使用的理解有限。基于PubMed/EMBASE(2016年1月至2024年7月)的有针对性检索,对临床试验用例进行了回顾,在试验设计和实施过程中具有实用主义元素,以及在原始(“母”)试验的延伸阶段利用RWD进行长期随访的临床试验进行了特征分析。总共描述了27个用例。有22个用例具有实用因素,几乎所有用例都采用随机化(n = 21, 95.5%)、开放标签设计(n = 20, 90.9%)和通常/标准护理(n = 13, 59.1%)作为比较。大多数产生了有效性和安全性的证据(n = 18, 81.8%),主要在糖尿病和心血管疾病领域(n = 14, 63.6%)。最常见的实用因素是广泛的资格标准,灵活的治疗管理,最少或没有随访,以及简化的终点收集。一半的用例使用了RWD(包括电子健康记录、索赔、注册表)(n = 4用于用从RWD中提取的附加信息丰富试验数据;n = 7用于将试验嵌入常规医疗保健数据库/系统)。此外,我们还确定了5个在原始“母”试验的扩展阶段使用RWD的用例(4个使用RWD进行长期随访,1个使用RWD构建基于临床试验基础设施的扩展研究的外部对照)。本综述强调了务实因素在提高试验效率、可推广性和长期结果证据生成方面的新作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
12.70
自引率
7.50%
发文量
290
审稿时长
2 months
期刊介绍: Clinical Pharmacology & Therapeutics (CPT) is the authoritative cross-disciplinary journal in experimental and clinical medicine devoted to publishing advances in the nature, action, efficacy, and evaluation of therapeutics. CPT welcomes original Articles in the emerging areas of translational, predictive and personalized medicine; new therapeutic modalities including gene and cell therapies; pharmacogenomics, proteomics and metabolomics; bioinformation and applied systems biology complementing areas of pharmacokinetics and pharmacodynamics, human investigation and clinical trials, pharmacovigilence, pharmacoepidemiology, pharmacometrics, and population pharmacology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信